Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avicanna ( (TSE:AVCN) ) has shared an announcement.
Avicanna has announced the first peer-reviewed publication from its Medical Cannabis Real-World Evidence (MCRWE) program, reporting results of a prospective observational study of physician-authorized medical cannabis for chronic pain, conducted through its MyMedi.ca platform and led by University Health Network’s Dr. Hance Clarke. The study, published in the Canadian Journal of Pain, found statistically significant improvements over 24 weeks in pain interference, pain intensity, anxiety, depressive symptoms and quality of life among patients who continued treatment, though changes did not reach minimal clinically important thresholds, underscoring the need for further randomized, placebo-controlled trials; Avicanna’s ongoing role in providing infrastructure and support for large-scale real-world evidence positions the company as an important contributor to clinical data generation in the evolving medical cannabis field.
The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Neutral.
The score is held back primarily by continued losses and negative cash flow despite strong revenue growth and improving gross margins, plus a weak technical trend (price below major moving averages and negative MACD). Valuation also screens poorly due to the negative P/E, consistent with the lack of current profitability.
To see Spark’s full report on TSE:AVCN stock, click here.
More about Avicanna
Avicanna Inc. is a commercial-stage, international biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, with an emphasis on medical applications and evidence-based integration of cannabis medicines into healthcare.
Average Trading Volume: 60,416
Technical Sentiment Signal: Sell
Current Market Cap: C$24.18M
For a thorough assessment of AVCN stock, go to TipRanks’ Stock Analysis page.